Josh Jennings
Stock Analyst at Morgan Stanley
(2.63)
# 2,136
Out of 4,944 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $32.18 | +64.70% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $308.48 | -2.75% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $1.42 | +1,308.45% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $18.90 | +233.33% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $1.08 | +548.15% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $77.68 | -48.51% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $32.18
Upside: +64.70%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $308.48
Upside: -2.75%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $1.42
Upside: +1,308.45%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $18.90
Upside: +233.33%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $1.08
Upside: +548.15%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $77.68
Upside: -48.51%